Methicillin-resistant staphylococcus aureus (MRSA) is an infection of the skin that occurs mostly in hospitals and healthcare facilities. It is treated with commonly used antibiotics and usually spreads from person to person by direct skin-to-skin contact. Physicians often find MRSA harder to treat than most other strains of staphylococcus aureus because it is sometimes resistant to commonly-used antibiotics such as methicillin. Some of the most commonly used antibiotics use for the treatment of MRSA include glycopeptides and lipoglycopeptides, oxazolidinones, lipopeptides, cephalosporin, and others. These drugs are used to kill or restrain Methicillin-resistant staphylococcus aureus infection.
Market Dynamics
Rising number of pipeline products, and increasing product launches & approval for the treatment of MRSA infection are some of the major factors responsible for the growth of global Methicillin-resistant staphylococcus aureus (MRSA) market. For instance, For instance, in 2018, Destiny Pharma received investigational new drug application from FDA for its new candidate, XF-73, a dicationic porphyrin molecule based nasal gel, to combat post-surgical infections of Methicillin-resistant Staphylococcus aureus (MRSA).
Key features of the study
• This report provides in-depth analysis of the global Methicillin-resistant staphylococcus aureus (MRSA) drugs market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2027), considering 2019 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Methicillin-resistant staphylococcus aureus (MRSA) drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Merck & Co., Inc., Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Melinta Therapeutics, Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics Plc., Paratek Pharmaceuticals, Inc., Debiopharm International SA., Innovation Pharmaceuticals Inc., and Basilea Pharmaceutica Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Methicillin-resistant staphylococcus aureus (MRSA) drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Methicillin-resistant staphylococcus aureus (MRSA) drugs market
Market Segmentation
• By Drug Class Insights (Revenue, USD Mn, 2021 - 2033)
o Glycopeptides and Lipoglycopeptides
o Oxazolidinones
o Lipopeptides
o Cephalosporin
o Tetracycline
o Others
• By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region Insights (Revenue, USD Mn, 2021 - 2033)
o North America
 U.S.
 Canada
o Latin America
 Brazil
 Argentina
 Mexico
 Rest of Latin America
o Europe
 Germany
 U.K.
 Spain
 France
 Italy
 Russia
 Rest of Europe
o Asia Pacific
 China
 India
 Japan
 Australia
 South Korea
 ASEAN
 Rest of Asia Pacific
o Middle East & Africa
 GCC Countries
 Israel
 Rest of Middle East & Africa
• Key Players
o Merck & Co.Inc.
o Pfizer Inc.
o AbbVie Inc.
o Teva Pharmaceutical Industries Ltd.
o Melinta Therapeutics, Inc.
o Cumberland Pharmaceuticals Inc.
o Nabriva Therapeutics Plc.
o Paratek Pharmaceuticals, Inc.
o Debiopharm International SA.,
o Innovation Pharmaceuticals Inc.
o Basilea Pharmaceutica Ltd.

Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
 Market Definition and Scope
o Executive Summary
 Market Snippet, By Drug Class
 Market Snippet, By Distribution Channel
 Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o CKD Stages Treatment Options
o Market Dynamics
 Drivers
 Restraints
 Market Opportunities
o Impact Analysis
o Pipeline Analysis
o Market Trends
o Recent Product Launch/Approvals
o Cost of Treatment
o Regulatory Scenario
o PEST Analysis
o Mergers, Acquisitions, and Partnerships
o Epidemiology
o Brilacidin Effectiveness
o Brilacidin Research Perspective
o Reimbursement Scenario (Medicare Part D Spending)
4. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, By Drug Class, 2021 – 2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2021 – 2033
 Segment Trends
o Glycopeptides and Lipoglycopeptides
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Oxazolidinones
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Lipopeptides
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Cephalosporin
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Tetracycline
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Others
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
5. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, By Distribution Channel, 2021 – 2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2021 – 2033
 Segment Trends
o Hospital Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Online Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Retail Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
6. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, By Region, 2021 – 2033, (USD Mn)
o Introduction
 Market Share Analysis, By Region, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, For Regions, 2021–2033
o North America
 Market Size and Forecast, By Drug Class, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o U.S.
o Canada
o Latin America
 Market Size and Forecast, By Drug Class, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
 Market Size and Forecast, By Drug Class, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
 Market Size and Forecast, By Drug Class, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
 Market Size and Forecast, By Drug Class, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
 Market Size and Forecast, By Drug Class, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country/Region, 2021 – 2033, (USD Mn)
o South Africa
o Central Africa
o North Africa
7. Competitive Landscape
o Heat Map Analysis
o Company Profiles
 Merck & Co., Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Pfizer Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 AbbVie Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Teva Pharmaceutical Industries Ltd.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Melinta Therapeutics, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Cumberland Pharmaceuticals Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Nabriva Therapeutics Plc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Paratek Pharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Debiopharm International SA.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Innovation Pharmaceuticals Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Basilea Pharmaceutica Ltd.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About us and Sales Contact